alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 48 studies with an author at University College London (GB) published 2018 (page 1 of 2) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study

✓ Peer-reviewed alzhub usefulness score 77 out of 100. The Lancet. Neurology 2018-02-01

We found a sequence to pathological changes, with rates of Aβ deposition in mutation carriers being significantly different from those in non-carriers first (across regions that showed a significant difference, at a mean of 18·9 years [SD 3·3] before expected onset), followed by hypometabolism (14·1 years [5·1] before expected onset), and lastly structural decline (4·7 years [4·2] before expected onset). 2 key findings →

Design: longitudinal study Participants: 346 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

✓ Peer-reviewed alzhub usefulness score 74 out of 100. PLoS medicine 2018-09-24

This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. 4 key findings →

Participants: 577 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 73 out of 100. Neurology 2018-07-27

Neuroinflammation and cerebrovascular dysfunction are early events occurring already at presymptomatic stages of AD and contribute to disease progression. 5 key findings →

Design: longitudinal study Participants: 508 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau

✓ Peer-reviewed alzhub usefulness score 71 out of 100. JAMA neurology 2018-08-01

After correcting for multiple comparisons using the Bonferroni procedure, we observed a statistically significant interaction between APOE-ε4 and sex on CSF total tau (β = 0.41; 95% CI, 0.27-0.55; P Conclusions and relevance We provide robust evidence of a stronger association between APOE-ε4 and CSF tau levels among women compared with men across multiple independent data sets. 5 key findings →

Design: cohort study Participants: 1,798 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies

✓ Peer-reviewed alzhub usefulness score 71 out of 100. PLoS medicine 2018-01-09

We found up to 270-fold genetic enrichment between FTD and RA, up to 160-fold genetic enrichment between FTD and UC, up to 180-fold genetic enrichment between FTD and T1D, and up to 175-fold genetic enrichment between FTD and CeD. 5 key findings →

Design: meta-analysis Participants: 192,886 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Accuracy of general hospital dementia diagnoses in England: Sensitivity, specificity, and predictors of diagnostic accuracy 2008-2016

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2018-04-25

Dementia diagnosis recording in general hospitals is increasing but remains less likely in some groups. 1 key finding →

Design: cohort study Participants: 21,387 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cognitive function trajectories and their determinants in older people: 8 years of follow-up in the English Longitudinal Study of Ageing

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Journal of epidemiology and community health 2018-04-24

The potential determinants of cognitive decline identified in this study, in particular modifiable risk factors, should be tested in the context of randomised controlled trials. 2 key findings →

Design: longitudinal study Participants: 626 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Neurology 2018-02-02

Baseline biomarkers largely do not predict risk for developing ARIA-E. ARIA-E was associated with significant longitudinal changes in several biomarkers, with larger reductions in amyloid PET and CSF p-tau and t-tau concentrations, and paradoxically greater hippocampal volume reduction and ventricular enlargement, suggesting that ARIA-E in bapineuzumab-treated cases may be related to increased Aβ efflux from the brain and affecting downstream pathogenic processes. 4 key findings →

Design: longitudinal study Participants: 1,512 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Mild cognitive impairment and progression to dementia in people with diabetes, prediabetes and metabolic syndrome: a systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Social psychiatry and psychiatric epidemiology 2018-09-04

The overall unadjusted pooled odds ratio for the progression of MCI to dementia in people with diabetes/MetS was 1.67 (95% CI 1.27-2.19); the pooled odds ratio for progression in diabetes + MCI was 1.53 (95% CI 1.20-1.97) and in people with MetS + MCI was 2.95 (95% CI 1.23-7.05). 4 key findings →

Design: meta-analysis Participants: 15 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2018-03-01

Elecsys CSF biomarker assays may provide reliable alternatives to PET in Alzheimer's disease diagnosis. 3 key findings →

Participants: 277 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Nature communications 2018-10-15

The heterogeneity of neurodegenerative diseases is a key confound to disease understanding and treatment development, as study cohorts typically include multiple phenotypes on distinct disease trajectories. 1 key finding →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Trends in dementia diagnosis rates in UK ethnic groups: analysis of UK primary care data

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Clinical epidemiology 2018-08-08

People from the black ethnic group had a higher incidence of dementia diagnosis and those from the Asian ethnic group had lower incidence compared with the white ethnic group. 5 key findings →

Design: cohort study Participants: 2,511,681 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2018-01-06

Circulating metabolites were consistently associated with cognition, dementia, and lifestyle factors, opening new avenues for prevention of cognitive decline and dementia. 4 key findings →

Participants: 25,872 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Age-accelerated cognitive decline in asymptomatic adults with CSF β-amyloid

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Neurology 2018-03-09

Compare cognitive and hippocampal volume trajectories in asymptomatic middle-aged and older adults with positive CSF markers of β-amyloid (Aβ) or tau to adults without an Alzheimer disease (AD)-associated biomarker profile. 4 key findings →

Design: cohort study Participants: 78 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Alzheimer's research & therapy 2018-07-28

A growing body of evidence suggests that the plasma concentration of the neurofilament light chain (NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer's disease (AD). 4 key findings →

Participants: 25 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed